Achaogen Inc. (NASDAQ:AKAO)‘s stock had its “hold” rating reaffirmed by Cowen and Company in a research report issued on Tuesday.

The analysts wrote, “Analysts Have Conflicting Sentiments on These Healthcare Companies: Achaogen (NASDAQ: AKAO), Ignyta Inc (NASDAQ: RXDX) and Halozyme (NASDAQ: HALO) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=79dde734e8&wpp_id=459272’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Have Conflicting Sentiments on These Healthcare Companies: Achaogen (NASDAQ: AKAO), Ignyta Inc (NASDAQ: RXDX) and Halozyme (NASDAQ: HALO)”

A number of other research firms have also issued reports on AKAO. Aegis began coverage on shares of Achaogen in a research note on Wednesday, November 2nd. They issued a “buy” rating and a $10.00 target price on the stock. SunTrust Banks Inc. reissued a “buy” rating and issued a $10.00 price target on shares of Achaogen in a report on Monday, September 26th. Wedbush reissued an “outperform” rating and issued a $10.00 price target on shares of Achaogen in a report on Tuesday, September 27th. Needham & Company LLC reissued a “hold” rating on shares of Achaogen in a report on Tuesday, August 9th. Finally, Zacks Investment Research downgraded shares of Achaogen from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.63.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) opened at 4.40 on Tuesday. The firm has a 50-day moving average of $4.75 and a 200 day moving average of $4.01. The company’s market cap is $117.39 million. Achaogen has a 52-week low of $2.59 and a 52-week high of $6.24.

Achaogen (NASDAQ:AKAO) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.20. Achaogen had a negative net margin of 147.80% and a negative return on equity of 137.24%. The business had revenue of $16.05 million for the quarter, compared to analyst estimates of $8.72 million. During the same period last year, the business posted ($0.48) EPS. Achaogen’s revenue was up 258.3% compared to the same quarter last year. Equities research analysts expect that Achaogen will post ($2.70) earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. acquired a new position in Achaogen during the first quarter worth approximately $704,000. Jacobs Levy Equity Management Inc. increased its position in Achaogen by 13.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 85,472 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 10,330 shares during the last quarter. Point72 Asset Management L.P. increased its position in Achaogen by 241.4% in the second quarter. Point72 Asset Management L.P. now owns 890,000 shares of the biopharmaceutical company’s stock worth $3,373,000 after buying an additional 629,309 shares during the last quarter. A.R.T. Advisors LLC acquired a new position in Achaogen during the second quarter worth approximately $142,000. Finally, Eagle Global Advisors LLC increased its position in Achaogen by 55.4% in the second quarter. Eagle Global Advisors LLC now owns 38,749 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 13,812 shares during the last quarter. 56.83% of the stock is owned by institutional investors.

About Achaogen

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

5 Day Chart for NASDAQ:AKAO

Receive News & Stock Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related stocks with our FREE daily email newsletter.